Boston Scientific Corporation $BSX Shares Purchased by Fisher Funds Management LTD

Key Points

• Fisher Funds Management increased its Boston Scientific stake by 17.1% in the second quarter, adding 146,900 shares for a total holding valued at approximately $43 million. Institutional investors and hedge funds collectively own 89.07% of BSX.
• Boston Scientific reported quarterly revenue of $5.44 billion and adjusted EPS of $0.86, exceeding analyst estimates, while revenue grew 7.5% year over year. The company also authorized a $5 billion share-repurchase program covering up to 6.4% of outstanding shares.
• Analyst sentiment remains broadly positive, with 24 Buy, five Hold, and two Sell ratings and a consensus “Moderate Buy” rating. The average price target is $71.62, well above the reported share price of $51.40.

Fisher Funds Management LTD raised its position in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 17.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,007,864 shares of the medical equipment provider's stock after acquiring an additional 146,900 shares during the period. Boston Scientific makes up 1.2% of Fisher Funds Management LTD's portfolio, making the stock its 22nd biggest position. Fisher Funds Management LTD owned about 0.07% of Boston Scientific worth $43,016,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in BSX. Brighton Jones LLC raised its holdings in shares of Boston Scientific by 0.8% in the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider's stock worth $2,445,000 after purchasing an additional 226 shares during the period. FWL Investment Management LLC purchased a new stake in shares of Boston Scientific during the 2nd quarter worth about $26,000. Main Street Financial Solutions LLC grew its holdings in shares of Boston Scientific by 35.3% during the 2nd quarter. Main Street Financial Solutions LLC now owns 7,556 shares of the medical equipment provider's stock worth $812,000 after purchasing an additional 1,971 shares during the period. Ieq Capital LLC increased its position in Boston Scientific by 97.0% during the 2nd quarter. Ieq Capital LLC now owns 123,592 shares of the medical equipment provider's stock worth $13,275,000 after purchasing an additional 60,860 shares in the last quarter. Finally, HUB Investment Partners LLC increased its position in Boston Scientific by 56.2% during the 2nd quarter. HUB Investment Partners LLC now owns 7,102 shares of the medical equipment provider's stock worth $763,000 after purchasing an additional 2,556 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Cheryl Pegus purchased 1,770 shares of the company's stock in a transaction that occurred on Wednesday, May 20th. The shares were purchased at an average price of $56.49 per share, with a total value of $99,987.30. Following the purchase, the director directly owned 1,770 shares of the company's stock, valued at approximately $99,987.30. This represents a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Edward J. Ludwig acquired 5,000 shares of the business's stock in a transaction on Friday, July 31st. The stock was purchased at an average price of $45.48 per share, for a total transaction of $227,400.00. Following the acquisition, the director directly owned 30,359 shares in the company, valued at $1,380,727.32. This represents a 19.72% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired a total of 204,322 shares of company stock valued at $9,939,221 in the last 90 days. Company insiders own 0.34% of the company's stock.

Boston Scientific Stock Up 0.4%

NYSE BSX opened at $51.40 on Thursday. The stock has a market cap of $74.49 billion, a PE ratio of 20.81, a P/E/G ratio of 1.12 and a beta of 0.56. Boston Scientific Corporation has a fifty-two week low of $42.20 and a fifty-two week high of $109.50. The business has a 50 day moving average price of $45.94 and a two-hundred day moving average price of $59.69. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The company had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. During the same quarter last year, the firm posted $0.75 earnings per share. The business's quarterly revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, sell-side analysts predict that Boston Scientific Corporation will post 3.3 EPS for the current fiscal year.

Boston Scientific announced that its Board of Directors has authorized a share repurchase plan on Monday, May 18th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock buyback plans are often an indication that the company's leadership believes its shares are undervalued.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. Deutsche Bank Aktiengesellschaft reaffirmed a "buy" rating and set a $60.00 price target on shares of Boston Scientific in a research report on Thursday, July 30th. Daiwa Securities Group lowered shares of Boston Scientific from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, April 29th. Zacks Research downgraded shares of Boston Scientific from a "hold" rating to a "strong sell" rating in a research note on Friday, June 5th. TD Cowen reduced their target price on shares of Boston Scientific from $61.00 to $56.00 and set a "buy" rating on the stock in a report on Thursday, July 30th. Finally, Weiss Ratings cut shares of Boston Scientific from a "hold (c-)" rating to a "sell (d+)" rating in a research report on Tuesday, July 7th. Twenty-four analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $71.62.

Boston Scientific Company Profile

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source